Revolutionizing Lung Cancer Management: AI-Powered Liquid Biopsy–Immunotherapy Synergy For Early Internist-Led Interventions In High-Risk Populations
Lung cancer continues to be a predominant global cause of death. Clinical outcomes are significantly influenced by the timely identification of high-risk populations, accurate diagnosis, and appropriate therapy selection. Progress in artificial intelligence (AI), liquid biopsy, and immunotherapy has opened new avenues...